BioPharmSignal logoBioPharmSignal

Biotech News

Bluejay Diagnostics Provides Corporate Update and 2026 Strategic Outlook

Bluejay Diagnostics (BJDX)Bluejay DiagnosticsCompany update

ACTON, Mass., March 06, 2026 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical diagnostics company developing rapid near-patient tests to improve patient outcomes in critical care settings, today provided a corporate update highlighting recent

Open original release

Related news

BJDXBluejay Diagnostics2025-11-10 12:30 EST

Bluejay Diagnostics Corporate Update: Advancing Clinical Milestones and Strategic Partnerships

BJDXBluejay Diagnostics2026-06-02 10:30 EST

Bluejay Diagnostics and Argonaut Manufacturing Services Announce Strategic Partnership

DGXQuest Diagnostics2026-06-29 12:16 EST

Quest Diagnostics Foundation Commits Nearly $5 Million to Improving Health Outcomes and Food Security in Miami-Dade County, Florida

LUCDLucid Diagnostics2026-07-30 12:30 EST

Lucid Diagnostics to Hold Second Quarter 2026 Business Update Conference Call and Webcast on August 13, 2026

DGXQuest Diagnostics2026-06-24 12:52 EST

Quest Diagnostics Receives New York State Approval for Haystack MRD®, Broadening Patient Access to ctDNA Minimal Residual Disease Testing

LUCDLucid Diagnostics2026-04-30 12:31 EST

Lucid Diagnostics to Hold First Quarter 2026 Business Update Conference Call and Webcast on May 14, 2026

FLGTFulgent Genetics, Inc.2026-03-17 20:31 EST

Fulgent Genetics Completes Acquisition of Bako Diagnostics and StrataDx

FLGTFulgent Genetics, Inc.2025-12-22 21:10 EST

Fulgent Genetics Agrees to Acquire Bako Diagnostics and StrataDx

ATOSAtossa Therapeutics, Inc.2025-01-23 13:15 EST

Atossa Therapeutics Issues Letter to Shareholders Highlighting 2024 Accomplishments and Outlook for 2025

AXDXAccelerate Diagnostics2025-03-21 17:52 EST

Accelerate Diagnostics Submits WAVE System and Gram-Negative Positive Blood Culture Menu to the FDA for 510(k) Clearance

View all latest news

Bluejay Diagnostics

Bluejay Diagnostics is a medical diagnostics company focused on rapid testing and blood-based diagnostic tools. Its business is centered on bringing point-of-care information to clinical settings rather than developing therapeutics.

Recent company news

BJDXBluejay Diagnostics2026-07-21 10:30 EST

Bluejay Diagnostics Announces Successful Completion of Enrollment in the SYMON-II Multicenter Clinical Validation Study

BJDXBluejay Diagnostics2026-06-06 00:13 EST

Bluejay Diagnostics Announces Closing of Up to $23.7 Million Private Placement Priced At-The-Market Under Nasdaq Rules

BJDXBluejay Diagnostics2026-06-02 16:19 EST

Bluejay Diagnostics Announces up to $23.6 Million Private Placement Priced At-the-Market Under Nasdaq Rules

BJDXBluejay Diagnostics2026-06-02 10:30 EST

Bluejay Diagnostics and Argonaut Manufacturing Services Announce Strategic Partnership

BJDXBluejay Diagnostics2026-05-07 20:01 EST

Bluejay Diagnostics Provides First Quarter 2026 Corporate Update

Stock data

Close
1.00 USD
Market cap
4.49M USD
Exchange
NASDAQ
Sector
MedTech
Location
United States